IBCL-124: Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL)

Here, we report interim results from ZUMA-5, a Phase 2 study of axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed/refractory iNHL. Adults with relapsed/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL) after ≥2 lines of thera...

Celý popis

Podrobná bibliografia

Vydané v:	Clinical lymphoma, myeloma and leukemia Ročník 20; s. S278
Hlavní autori:	Jacobson, Caron A., Chavez, Julio C., Sehgal, Alison R., William, Basem M., Munoz, Javier, Salles, Gilles, Casulo, Carla, Munshi, Pashna N., Maloney, David G., Vos, Sven de, Reshef, Ran, Leslie, Lori A., Yakoub-Agha, Ibrahim, Oluwole, Olalekan O., Fung, Henry C., Plaks, Vicki, Yang, Yin, Lee, Jennifer, Avanzi, Mauro P., Neelapu, Sattva S.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Elsevier Inc 01.09.2020
Predmet:	CAR T cell therapy chimeric antigen receptor IBCL indolent B-cell lymphoma IBCL chimeric antigen receptor CAR T cell therapy indolent B-cell lymphoma
ISSN:	2152-2650, 2152-2669
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!